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ABSTRACT 
 
KRISTEN BRADBURN OLIVER 
An Analysis of Selected Predictive Factors Associated with Adolescent HPV Vaccination 
Initiation and Completion Rates in the United States:  2011 National Immunization 
Survey - Teen 
(Under the direction of Christine Stauber, Faculty Member) 
 
Background 
Human papillomavirus (HPV) is the most common sexually transmitted infection in the 
United States, and adolescents have the highest incidence.  To decrease the burden of 
HPV and HPV-associated cancers, two vaccines were developed and require a 3 dose 
series.  This study assesses factors that may predict whether a teen will either initiate or 
complete the vaccine series. 
 
Methods 
National Immunization Survey -Teen 2011 data was used to assess demographic (age, 
sex, and race/ethnicity) and socioeconomic (poverty and insurance status) factors as they 
related to vaccine initiation and completion.  Bivariate and multivariate analyses were 
used to determine strength of association. 
 
Results 
Females were more likely than males to initiate and complete the series. Compared to 
whites, Hispanic teens were 1.5 times more likely to initiate but less likely to complete. 
Blacks were least likely to complete. Teens below the poverty line were more likely to 
initiate compared to teens above poverty but less likely to complete.  Teens with at least 
one form of health insurance were 1.2 times more likely to complete than those with no 
insurance. 
 
Conclusion 
HPV vaccination rates are increasing and need to continue to do so.  Emphasis needs to 
be placed on completing the series to confer complete resistance.  This is especially true 
for blacks and Hispanics who are at a higher risk of HPV-related morbidities. 
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CHAPTER I 
INTRODUCTION 
1.1 Background 
Human papillomaviruses (HPVs) are a group of approximately 150 related viruses, 
which attack the body’s epithelial cells, such as those found on the skin, mouth, and 
genitals.  More than 40 of these viruses are classified as genital human papillomaviruses 
and can be spread through skin-to-skin contact during vaginal, anal, and oral sex [1]. 
Most sexually active men and women will be infected with one or more genital HPVs at 
some point in their lives [2].  Because most infected persons exhibit no symptoms, these 
40 HPVs are unknowingly spread and make up the most prevalent sexually transmitted 
infection in the United States [2].  Approximately half of the new HPV infections each 
year are found among young people (ages 15-24), even though they only make up a 
quarter of the sexually active population [2].   
Sexually transmitted HPVs are divided into two categories based on oncogenic, or 
cancer-causing, properties.  Low-risk HPVs do not cause cancer but can cause skin warts 
on or around the genitals or anus.  High-risk HPVs can cause cancer if the body does not 
rid itself of the virus.  Common HPV-associated cancers are cervical, anal, vaginal, 
vulvar, penile, and oropharyngeal.  [4] 
HPVs are highly preventable by abstaining from sexual contact or correct and 
consistent use of condoms for those who are sexually active.  To decrease the burden of 
HPV and associated cancers, two vaccines were developed, targeting the most common 
genital HPVs.  Quadrivalent Gardasil ®, approved by the FDA on June 8, 2006, prevents 
infections with HPV high-risk types 16 and18, as well as low-risk types 6 and 11 [4].  
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Bivalent Cervarix ®, approved by the FDA on October 16, 2009, prevents infections with 
HPV high-risk types 16 and 18 [5].  Both vaccines require a 3 dose series given over a 6-
month period [4].  
The Advisory Committee on Immunization Practices (ACIP) has established 
vaccination guidelines for both quadrivalent (HPV4) and bivalent (HPV2) vaccines, 
which were licensed for use among females aged 9 – 26 years for prevention of vaccine 
HPV-type-related cervical cancer, cervical cancer precursors, and anogenital warts [4].  
Ideally, the vaccine series should be completed before the onset of sexual activity and 
HPV exposure.  The committee recommends routine vaccination of females aged 11 or 
12 with 3 doses of either vaccine.  In 2011, the quadrivalent vaccine was licensed for use 
among males aged 11 to 12.  [3] 
 
1.2 Purpose of Study 
The United States government has made HPV and its associated cancers a priority by 
including them in several Healthy People 2020 objectives. 
 
Immunization and Infectious Diseases Objectives: 
• IID-11:  Increase routine vaccination coverage for adolescents [6]. 
• IID-11.4: Increase the vaccination coverage level of three doses of HPV vaccine 
for females by age 13-15 years.  The target is 80% coverage of females, an 
increase from the 16.6% coverage in 2009 [6]. 
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Sexually Transmitted Diseases Objectives: 
• STD-9:  Decrease proportion of females with HPV infection [7]. 
Cancer Objectives: 
• C-4:  Decrease death rate from cancer of uterine cervix rate by 10%.  Target is 
2.2/100, 000 [8]. 
• C-10:  Decrease invasive uterine cervical cancer rates by 10%.  Target is 
7.1/100,000 [8]. 
Adolescents have the highest incidence of HPV infections in the United States 
compared to other age groups [2].  If they are underutilizing vaccination opportunities to 
decrease HPV infection and potential cancer morbidity, it is important to examine factors 
that may predict initiation and completion of the vaccine series.  Understanding these 
characteristics can lead to the development of successful public health practices, targeting 
specific populations in order to increase vaccination coverage in the United States. 
 
1.3 Research Questions 
To further investigate predictors of why adolescents in the United States aged 13 to 
17 in the 2011 National Immunization Survey – Teen initiated or completed the human 
papilloma virus vaccine series, the following questions will be examined: 
1. Is race/ethnicity associated with initiation or completion of the HPV vaccine 
series among adolescents in the United States? 
2. Is gender associated with initiation or completion of the HPV vaccine series 
among adolescents in the United States? 
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3. Is age associated with initiation or completion of the HPV vaccine series among 
adolescents in the United States? 
4. Is poverty status associated with initiation or completion of the HPV vaccine 
series among adolescents in the United States? 
5. Is health insurance status associated with initiation or completion of the HPV 
vaccine series among adolescents in the United States? 
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CHAPTER II 
REVIEW OF THE LITERATURE 
2.1 HPV Virology and Immunology 
Human papillomaviruses are non-enveloped, double-stranded DNA viruses in the 
family Papillomaviridae.  Isolates of HPV are classified as “types” and numbers are 
assigned based on order of discovery [9].  All HPVs have an 8 kb circular genome 
enclosed in a capsid shell composed of the major (L1) and minor (L2) capsid proteins.  
The genome encodes several early genes that enable viral transcription and replication 
and interact with the host genome.  Immortalization and transformation functions are 
associated with the E6 and E7 early genes, which code for the primary oncoproteins 
found in high-risk types of HPV [10]. 
Members of the Papillomaviridae family infect cells located in the basal layer of 
the epithelium.  By using the cellular replication machinery of the differentiating cells, 
the viral genome is amplified.  Infection causes non-dividing epithelial cells to maintain 
an active state of cell division.  This often results in a thickened epithelial lesion.  As the 
cells exfoliate from the epithelium, the virus is shed [4].  Because they are restricted to 
the epithelium, HPV infections often go unnoticed by the host’s immune system [11]. 
The majority of HPV infections are transient and asymptomatic, causing no 
clinical problems.  With the median duration of new infections at 8 months, 70% of HPV 
infections clear within one year and 90% clear within 2 years [12].  HPV infections 
cannot be treated.  While HPV-associated lesions are typically addressed through 
cryotherapy, electrocautery, laser therapy, and surgical excision, this does not eliminate 
the infection from the host [13]. 
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2.2  Epidemiology of HPV Infection in the United States 
Genital HPV infection is primarily transmitted by genital contact, usually though 
sexual intercourse [14].  Transmission of HPV through other types of genital contact 
(oral-genital, manual-genital, genital-genital) has been identified but is less common [15].  
Nonsexual transmission of genital HPV can include mother to her newborn baby [16]. 
Incidence and prevalence of HPV is limited, since HPV is not a reportable 
disease.  For many infected with HPV, no symptoms develop, therefore no diagnosis is 
attempted.  It is estimated 14.1 million new infections occur in the United States each 
year [17].  With 79 million currently infected, the highest prevalence is among women 
20-24 years of age [17].  The most consistent predictors of infection have been measures 
of sexual activity, most importantly the number of sexual partners, both lifetime and 
recent [12]. 
 
2.3 Epidemiology of HPV-Associated Cancers  
2.3.1 Cervical Cancers 
Cervical cancers are divided into two categories:  squamous cell cancers and 
adenocarcinomas.  Three fourths of cervical cancers in the United States are squamous 
cell, while the remaining one fourth are adenocarcinomas [4].  These cancers develop 
slowly, over decades, and are often preceded by high-grade cervical lesions detected 
though routine Papanicolaou (Pap) smears [18].  Cervical lesions are classified as 
cervical intraepithelial neoplasias (CIN) grades 1, 2, or 3, based on the increasing degree 
of abnormality of cervical cells.  CIN 1 spontaneously clears in 60% of cases and 
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progresses to cancer in only 1% of patients.  CIN 2 and 3 are less likely to clear 
spontaneously and more likely to progress to cancer without treatment [4]. 
In 2009, the incidence rate of cervical cancer was 8.1 per 100, 000 [19].  (Note all 
rates will be presented in this paper per 100,000.)  With the introduction of the Pap smear 
in the 1940’s, cervical cancer incidence rates have decreased approximately 75% and 
death rates approximately 70% [4].  Early detection allows for treatment before cervical 
lesions progress to cancer.  Interestingly, the decrease in incidence is attributed to 
squamous cell carcinoma, as the incidence of adenocarcinoma has remained relatively 
stable [4].   
There are documented racial and ethnic disparities in invasive cervical cancer 
(ICC) rates.  Blacks are twice as likely and Hispanic whites are two to three times as 
likely as whites to be diagnosed with ICC [18].  Hispanic whites have the highest age-
adjusted incidence rate of cancer overall (24.2), as well as the highest incidence rates for 
both squamous cell carcinoma and adenocarcinoma (18.3 and 4.6, respectively) [18].  
Whites have the lowest rate of cervical cancer overall (10.8) and squamous cell 
carcinoma (7.2) [18].  Blacks have the lowest rate of adenocarcinoma (2.3) [18].  In a 
study of county demographics, incidence rates seemed to be higher in counties with lower 
mean annual household incomes and higher proportions of people living below the 
poverty level [18]. 
Human papillomavirus types 16, 18, 31, and 45 are the most common culprits for 
cervical cancer diagnoses [20].  HPV types 16 and 18 account for 70% of cervical 
cancers and 50% of precancerous lesions worldwide [20].    These two high-risk types are 
8 
 
found in high-grade cervical lesions and linked to 68% of squamous cell cancers and 83% 
of adenocarcinomas [4].   
 
2.3.2 Other HPV-Associated Cancers 
Cervical cancer is not the only cancer associated with HPV infection.  Other 
cancers linked to HPV are oropharyngeal, anal, penile, vulvar, and vaginal.  In 2009, all 
HPV-associated cancers accounted for 3.3% and 2.0% of total cancer cases among 
women and men, respectively, in the United States [20].  Overall, oropharyngeal and 
cervical cancers were the two most common HPV-associated cancers, where 37.3% were 
oropharyngeal and 32.7% were cervical [20].  For women, 53.4% of these cancers were 
cervical.  For men, 78.2% of these cancers were oropharyngeal [20]. 
Data collected between 2005 and 2009 regarding incidence rates of the different 
HPV-associated cancers showed several differences based on sex, race/ethnicity, and 
socioeconomic status [20].  Oropharyngeal cancers rates were highest among white and 
black men (8.5 and 7.9) [20].  Anal and vulvar cancers were highest among white women 
(2.6 and 2.5) [20].  Vaginal cancers were highest among black women (0.8).  Penile 
cancers were highest among American Indian and Alaska Native (AI/AN) men (2.0) [20].  
Asian-Pacific Islander (API) men and women have the lowest rates of all cancers, except 
vaginal, in which AI/AN women have the lowest rate [20]. 
As stated before, cervical cancer rates are declining in the United States.  
However, a disturbing trend of increased rates of other HPV-associated cancers is starting 
to emerge.  Anal and oropharyngeal cancer age-adjusted rates climbed between 2000 and 
2009.  The average annual percent change (APC) for anal cancers has had a statistically 
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significant increase for white men (2.6), white women (3.7), black men (5.6) and black 
women (2.5) [20].  The APC for oropharyngeal cancers has significantly increased for 
white men (3.9) and white women (1.7) [20].  The overall incidence rate of anal cancer 
has increased twofold from 1975 to 2009 in both men and women.  The burden of this 
cancer is highest among women [20]. 
2.4 Overview of Available Vaccines 
Two vaccines were developed to target the most common genital HPVs.  
Quadrivalent (HPV4) Gardasil ® by Merck & Company prevents infections with HPV 
high-risk types 16 and18, as well as low-risk types 6 and 11 [4].  Bivalent (HPV2) 
Cervarix ® by GlaxoSmithKline prevents infections with HPV high-risk types 16 and 18 
[5].  Both vaccines require a 3 dose series given over a 6-month period [4].  
Both vaccines contain virus-like particles (VLPs) composed of empty capsids 
formed by self-assembly of viral L1 proteins, which were created through recombinant 
DNA technology.  The VLPs do not contain viral DNA and are not infectious.  The 
capsids are geometrically similar to native HPV virions and elicit the host immune 
system to create neutralizing antibodies.  The HPV4 vaccine uses full-length L1 protein 
from HPV types 6, 11, 16, and 18.  Its proprietary adjuvant is composed of amorphous 
aluminum hydroxyphosphate sulfate.  The HPV2 vaccine uses C-terminally truncated L1 
protein from HPV types 16 and 18.  Its proprietary adjuvant is composed of 
monophosphoryl-lipid A absorbed to aluminum chloride. [21] 
Both vaccines require intramuscular injection of a three dose series administered 
at months 0, 2, and 6 [21].  The Advisory Committee on Immunization Practices (ACIP) 
recommends either HPV2 or HPV4 to be administered to females aged 11 or 12 years.  
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Only HP4 is recommended for males aged 11 or 12.  Vaccination is acceptable for 
children as young as 9 years of age, and catch-up is recommended for adolescents aged 
13 – 26.  ACIP recommends 11-12 years in order to fully vaccinate teens before sexual 
debut [22].  Even though providers recommend annual well checkup visits until the age 
of 21, studies have shown that frequency of these visits falls after the age of 12, possibly 
due to completion of vaccines required for school attendance [23].  Also, in 2009, the 
Youth Behavioral Risk Survey showed 5.9% of respondents had their first sexual 
experience before the age of 13 [22].   
 
2.4.1 HPV4 / Gardasil®  
For HPV-naïve women in trial studies, the vaccine efficacy over an average 3.6-
year follow-up was 98-100% against cervical lesions (CIN 1-3 or Adenocarcinoma in 
situ) related to vaccine-type HPV and 95-96% against external genital lesions (vulvar 
intraepithelial neoplasia (VIN) 1-3, vaginal intraepithelial neoplasia (VaIN) 1-3, or warts) 
[21].  For all women included in trial studies, regardless of previous HPV exposure, the 
vaccine efficacy was 45-69% against cervical lesions and 76-80% against genital lesions 
related to vaccine-type HPV [21].  There seems to be cross-protection against non-
vaccine-type HPV abnormalities.  The vaccine efficacy for HPV-naïve women was 43% 
for any type HPV related CIN 2 or worse and 55-83% for any external lesion [21].  For 
all women studied, the efficacy was 19% for any CIN 2 or worse and 30-62% for any 
external lesion [21]. 
In women with previous HPV exposure but no active infection, the quadrivalent 
vaccine was shown to protect against reinfection or reactivation of the HPV type to which 
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she had previously been exposed [21].  A natural infection that had been cleared, 
however, was found to not protect against reinfection of the same HPV type.  The 
vaccine was, also, able to protect these women against the vaccine types to which she had 
not yet been exposed [21].  Women with active vaccine-type HPV infections or existing 
HPV-related lesions do not benefit from receipt of the vaccine.  While HPV4 targets 
HPV types 6, 11, 16, and 18, the vaccine was found to provide cross-protection against 
persistent infection and lesions caused by other types of high-risk HPV, including 31, 33, 
45, 52, and 58 [21]. 
 
2.4.2 HPV2 / Cervarix ®  
For women HPV-naïve in trial studies, the vaccine efficacy was 93-100% against 
vaccine-type associated CIN 2 or worse [23].  For incident and persistent infections, the 
vaccine was 95-100% effective [23].  Similar to the quadrivalent vaccine, the bivalent 
vaccine is effective in the reduction of reinfection or reactivation of previously acquired 
vaccine-type infections and not effective for women with an active HPV infection [23].  
Cross-protection against other high-risk types of HPV is also conferred with this vaccine, 
namely 31, 33, and 45 [23]. 
The bivalent vaccine elicits a higher immune response to HPV types 16 and 18, 
the two most common oncogenic HPV types, than the quadrivalent vaccine [24].  
Neutralizing antibody titers against types 16 and 18 were between 4 and 9 times higher in 
women having received the bivalent vaccine [24]. 
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2.4.3 Vaccine Efficacy in the United States 
In a recent study, data collected from the annual National Health and Nutrition 
Examination Surveys (NHANES) was used to determine the vaccine’s efficacy thus far in 
the United States [25].  Vaccine-type HPV prevalence was determined among females 
aged 14 – 19 years between 2003 and 2010.  Prevalence before the vaccine was 
introduced (2003-2006) was compared with prevalence after the vaccine was introduced 
(2007-2010). Vaccine-type HPV prevalence fell from 11.5% (95% CI 9.2-14.4) in the 
pre-vaccine era to 5.1% (95% CI 3.8-6.6) in the vaccine era [25].  This decline of 56% 
(95% CI 38-69) was the only significant change in prevalence among the different age 
groups studied.  Despite low vaccine uptake, the vaccine is proving to be effective in the 
prevention of vaccine-type HPV in the United States among girls aged 14 – 19 years [25]. 
 
2.5 Barriers to Vaccine Initiation and Completion 
2.5.1 Physician Barriers 
Association between provider recommendation and HPV vaccine initiation has 
been clearly established [26].  While the vaccine is acceptable for children as young as 9 
years old, ACIP asks providers to recommend the series to 11 and 12 year olds at their 
annual well checkup visit.  This age group is targeted for several reasons.  First, this 
group is, for the most part, not sexually active, and ACIP believes this vaccine needs to 
be completed before sexual debut.  Second, this age group is still coming to the provider 
for well checkups [22].  A recent study shows that the number of annual well checkups 
decreases sharply after 12 years of age, where one-third of 13 to 17 year olds had no well 
checkup.  Another 40% had only one well checkup visit during that same time [27].  
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Third, these providers, typically pediatricians, are most experienced with vaccine 
administration [22]. 
Many providers have admitted to not recommending the HPV vaccine series to 11 
and 12 year olds for several of their own reasons.  There are many vaccines to administer 
at this well checkup.  There is an assumption that adding another vaccine may be 
overwhelming to the family.  Providers feel they don’t have the time to explain the need 
for this vaccine especially since is not mandatory [22].  Many providers admit having 
difficulty discussing this vaccine with parents of younger children, since it deals with a 
disease associated with sexual activity [28].  If a parent hesitates when approached, the 
provider will not push the subject further [26].  Because of these reasons, many providers 
tend to recommend the HPV vaccine to older girls [28].   
 
2.5.2 Parental Barriers 
When providers address the subject of HPV vaccination it is, at times, met with 
negative parental attitudes.  Parents may choose to not vaccinate their adolescent for a 
variety of reasons: mainly vaccine safety and efficacy [28].  Often, the HPV vaccine will 
be the only vaccine refused at a well checkup, therefore this refusal cannot be attributed 
to an overall negative attitude toward vaccines.  It is, also, not uncommon for parents to 
ask to delay vaccination for a year or two.  Reasons for this delay can typically be 
attributed to perceived lack of adolescent sexual activity and low risk of HPV infection 
[28]. 
When parents decide to vaccinate their adolescent, the number of shots needed for 
complete immunity poses an issue.  Future scheduling, time, transportation, and cost are 
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all barriers for the second and third shots.  Since the second shot is two months after the 
first and the third four months after that, remembering to schedule an appointment with 
the provider often slips through the cracks.  If that barrier is overcome, parents have to 
find time to take their child back to the provider’s office; this could be time from work or 
other, more pressing, family obligations.  If a parent can find time to return for the final 
two shots, transportation may not be available or difficult to come by.  Even though this 
vaccine series is typically covered by insurance (VFC, Medicaid, and private), a well-
visit co-pay could pose an issue for the parent [29]. 
 
2.5.3 Adolescent Barriers 
Studies have shown teens play a minimal role in the decision to receive, delay or 
refuse the HPV vaccine, deferring to their parent and provider.  The United States 
adolescent population is at a higher risk of acquiring HPV than any other age group [28].  
However, a recent study shows that only 21-46% of young women perceive themselves at 
risk for HPV infection [30].  Their lack of risk awareness and desire to advocate for 
themselves could be seen as a barrier to vaccine receipt. 
 
2.6 Disease Status and Vaccine Uptake 
While a recent study shows that HPV vaccine coverage is increasing, half of the 
adolescent population still remains unvaccinated.  Completion rates lag for those in the 
populations at highest risk for HPV morbidity [31].  Black and Hispanic women and 
women living in greater poverty experience the highest incidence and mortality rates due 
to cervical cancer.  Previous research shows significant disparities in HPV vaccine 
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completion rates based on race/ethnicity.  The populations at greatest risk of cervical 
cancer are not fully protected against the virus [29].  According to the CDC, 31.7% of 
blacks and 41.6% of Hispanics completed the vaccine series in 2011.  The same report 
shows that 39.0% of adolescents below the poverty line and 33.4% at or above the 
poverty line completed the series [32]. 
 
2.7 Summary 
The HPV vaccine series is still relatively new, and knowledge of issues regarding 
initiation and completion continue to evolve.  This study looks at specific demographic 
and socioeconomic factors that were involved with adolescents receiving this vaccine in 
2011, the most recent year of published data.  It is with the hope of developing public 
health initiatives in light of the above barriers associated with initiation and completion 
of the HPV vaccine series that this study is being conducted. 
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CHAPTER III 
METHODS 
3.1 Data Source 
The data in this study were obtained from the 2011 National Immunization 
Survey (NIS)-Teen.  The NIS is a publicly available database, containing de-identified 
information and is sponsored by the National Center for Immunizations and Respiratory 
Diseases (NCIRD).  It is conducted jointly by NCIRD and the National Center for Health 
Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC).  The NIS 
annual survey is used to assess progress towards goals of increased childhood 
vaccinations set by the Childhood Immunization Initiative (CII), which was established in 
1996 by President Bill Clinton.  NIS is targeted to children aged 19-35 months living in 
the United States at the time of the survey.  NIS-Teen was developed in 2006 for children 
aged 13 to 17 to measure progress toward Healthy People 2010 goals to increase routine 
vaccination coverage levels for adolescents.  [33] 
Data collected are used to produce estimates of vaccination coverage rates for all 
childhood vaccinations recommended by the Advisory Committee on Immunization 
Practices (ACIP).  This two-part list-assisted random-digit-dialing (RDD) telephone 
survey starts collecting data by interviewing households in all 50 States, the District of 
Columbia, U.S. Virgin Islands, and selected large urban areas each quarter. For the 
second part of the survey, to assure accuracy and precision of vaccination data collected, 
parents and guardians of NIS-eligible children are then asked for consent to contact 
children’s vaccination providers via mail.  Survey participation is voluntary and 
confidential. [33]  
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In 2011, the survey design was altered to account for the increased number of 
households in the United States without a landline telephone.  Data is now collected on 
both landlines and cell phones.  The cell phone sample was selected from all banks of cell 
phone numbers, not just those containing at least one directory-listed residential 
telephone number; therefore the cell phone sample is considered to be RDD without list 
assistance.  The U.S. Virgin Islands landline interviews are also RDD without list 
assistance and no cell phone data was collected.  Both landline and cell-phone interviews 
began January 6, 2011 and ended February 8, 2012. [33] 
 
3.2 Study Population 
The target population for NIS-Teen was children aged 13 to 17 years old living in 
non-institutionalized households in the United States at the time of the interview. If a 
household with a 19-35 month old child is identified and the NIS interview is completed, 
the household is then screened for the presence of any 13-17 year old children.  
Households that do not have a 19-35 month old child are immediately screened for the 
presence of any 13-17 year old children.  If household contains one or more children in 
the appropriate age range, a teen is randomly chosen and the adult who is most 
knowledgeable about the teen’s vaccination is interviewed.  With the parent or guardian’s 
consent, NIS-Teen will follow-up via mail with the teen’s vaccination provider, 
requesting information on the patient’s vaccination status from medical records. [33] 
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3.3 Study Measures and Variables 
Two dependent variables were chosen for this study.  The first dependent variable 
assessed adolescents who initiated the HPV vaccine series.  Data regarding the total 
number of HPV shots received during the study period were re-coded to reflect this 
variable.  If a teen had no HPV shots, he or she was considered to not have initiated the 
vaccine series.  If a teen had one or more HPV shots, he or she was considered to have 
initiated the series.  The second dependent variable assessed adolescents who completed 
the HPV vaccine series after having initiated the series.  Data regarding the total number 
of HPV shots received during the study period were re-coded to reflect this variable.  If a 
teen had one or two HPV shots, he or she was considered to have initiated but not 
completed the vaccine series.  If a teen had three or more HPV shots, he or she was 
considered to have completed the vaccine series. 
Five independent variables were chosen for this study.  The three demographic 
variables were sex, age, and race/ethnicity.  The two socioeconomic variables were 
poverty status and health insurance status.  Race/ethnicity was coded as non-Hispanic 
white, non-Hispanic black, Hispanic, and non-Hispanic other race and multi-race.  The 
Hispanic category included teens who were identified as Mexican, Mexican-American, 
Central American, South American, Puerto Rican, Cuban, or other Spanish-Caribbean.  
Non-Hispanic other race and multi-race included Native American, Alaskan native, 
Asian, Native Hawaiian, Pacific Islanders, and those who identified teens as “Other.”   
Poverty status was re-coded by NIS into three groups:  above poverty and more 
than $75K, above poverty but less than or equal to $75K, and below poverty.  These 
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numbers are based on the 2009 Census poverty threshold of $14,787 in a two-person 
household with 1 child under the age of 18 [34]. 
Health insurance was re-coded into a dichotomous variable in the current study.  
If the teen was covered by any of the following: employer or union health insurance, 
Medicaid, S-CHIP, Indian Health Services, Military/Tricare/CHAMPUS/CHAMP-VA, 
or other form of health insurance, he or she was considered to have health insurance.  All 
other teens were considered to be without health insurance. 
 
3.4 Statistical Analysis 
Descriptive statistics were created to describe the population sample.  Using 
binary logistic regression analysis, odds ratios were calculated along with 95% 
confidence intervals and p-value.  A p-value of <0.05 was considered a statistically 
significant association between each demographic and socioeconomic variables as they 
relate to either initiation or completion of the HPV vaccine series. 
Multivariate logistic regression analysis was also performed where all 
demographic and socioeconomic variables were considered at once.  Odds ratios were 
calculated along with 95% confidence intervals and p-value, where a p-value of <0.05 
was considered a statistically significant association. 
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CHAPTER IV 
RESULTS 
4.1 Frequencies and Descriptive Statistics 
Frequencies and descriptive statistics about the study sample are detailed in 
Tables 1 through 3.  The sample size of the 2011 NIS-Teen included 39 839 adolescents, 
where 52.2% were male and 47.8% were female.  Data regarding HPV vaccination was 
available for 38 136 adolescents and 28 191 (73.9%) of those adolescents had not 
initiated the HPV vaccination series. 
The following information describes adolescents who had at least one HPV shot 
in 2011 (Tables 2 and 3).  Females were most likely to initiate (84.2%) and complete 
(93.3%) the vaccine series.  While there was a relatively even distribution of the five age 
groups, 16 year olds were the most represented (20.7%) and 17 year olds were the least 
represented (19.3%).  Seventeen year olds were most likely to initiate (22.7%) and 
complete (25.5%) the vaccine series, while 13 year olds were least likely to initiate 
(15.3%) and complete (12.5%).  The majority of teens were non-Hispanic white (64%), 
while the least represented race/ethnicity was non-Hispanic other race and multi-race 
(8.5%).  White teens were more likely to initiate (62.9%) and complete (68.4%) the 
vaccine series, while non-Hispanic other race and multi-race were least likely to initiate 
(8.3%) and complete (7.8%). 
Of those surveyed where information on income and health insurance was 
obtained, the majority of the study population reported an annual family income above 
the U.S. 2009 Census Bureau poverty threshold and greater than $75,000 (40.7%) and 
reported having one or more form of health insurance (61.8%).  Teens above the poverty 
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threshold and greater than $75,000 were more likely to initiate (45.1%) and complete 
(48.1%) the vaccine series, while those below the poverty limit were least likely to 
initiate (16.9%) and complete (14.6%).  Teens with at least one form of health insurance 
were most likely to initiate (63.4%) and complete (65.8%) the vaccine series. 
 
 
Table 1. HPV Vaccine Receipt Data 
 
Receipt of at least one 
HPV vaccine shot N (%) 
Yes 9945 
No 28191 
 Total 38136* 
 
*1703 members of the NIS-Teen 2011 vaccination study population were excluded due to 
lack of information regarding HPV vaccine status. 
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Table 2. Demographic Characteristics and Vaccination Status of NIS-Teen 2011 
HPV Vaccination Study Population 
 
Demographic 
Characteristic 
N (%) Did Not 
Initiate Series 
N (%) 
Initiated Series 
N (%) 
Completed Series 
N (%) 
    28191 (73.9) 
out of 38136* 
9945 (26.1) out 
of 38136* 
5201 (52.3) out of 
9945 
SEX         
Male 20809 (52.2) 18299 (64.9) 1571 (15.8) 349 (6.7) 
Female 19030 (47.8) 9892 (35.1) 8374 (84.2) 4852 (93.3) 
Total 39839 28191  9945 5201 
          
AGE         
13 7802 (19.6) 5950 (21.1) 1518 (15.3) 651 (12.5) 
14 8108 (20.4) 5966 (21.2) 1853 (18.6) 887 (17.1) 
15 7997 (20.1) 5535 (19.6) 2109 (21.2) 1130 (21.7) 
16 8243 (20.7) 5654 (20.1) 2211 (22.2) 1205 (23.2) 
17 7689 (19.3) 5086 (18.0) 2254 (22.7) 1328 (25.5) 
Total 39839 28191 9945 5201 
          
RACE/ETHNICITY         
Non-Hispanic White 25809 (64.8) 18837 (66.8) 6259 (62.9) 3559 (68.4) 
Non-Hispanic Black 4938 (12.4) 3481 (12.3) 1114 (11.2) 419 (8.1) 
Hispanic 5693 (14.3) 3520 (12.5) 1745 (17.5) 818 (15.7) 
Non-Hispanic & 
Multi-race 
3399 (8.5) 2353 (8.3) 827 (8.3) 405 (7.8) 
Total 39839 28191 9945 5201 
*1703 members of the NIS-Teen 2011 vaccination study population were excluded 
due to lack of information regarding HPV vaccine status. 
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Table 3. Socioeconomic Characteristics and Vaccination Status of NIS-Teen 2011 
HPV Vaccination Study Population 
 
Demographic 
Characteristic 
N (%) Did Not 
Initiate Series 
N (%) 
Initiated Series 
N (%) 
Completed Series 
N (%) 
POVERTY STATUS         
Above Poverty ( > 
$75K) 16234 (40.7) 11595 (43.8) 4248 (45.1) 2380 (48.1) 
Above Poverty ( => 
$75K) 15438 (38.8) 11231 (42.5) 3583 (38.0) 1845 (37.3) 
Below Poverty 5747 (14.4) 3631 (13.7) 1593 (16.9) 720 (14.6) 
Unknown 2420 (6.1)       
Total 39839 26457 9424 4945 
  
        
INSURANCE         
Has no insurance 15208 (38.2) 10736 (38.1) 3640 (36.6) 1781 (34.2) 
Has at least one form 
of insurance 24631 (61.8) 17455 (61.9) 6305 (63.4) 3420 (65.8) 
Total 39839* (100) 28191 9945 5201 
*1703 members of the NIS-Teen 2011 vaccination study population were excluded due to 
lack of information regarding HPV vaccine status. 
 
 
 
4.2 Demographic characteristics 
Bivariate analysis using logistic regression assessed the association of 
demographic characteristics with the initiation and completion of the HPV vaccine series.  
The results are shown in Tables 4 and 5.  In this study, sex played a significant role in 
both the initiation (OR=9.9, p=<0.001) and completion (OR=4.8, p=<0.001) of the 
vaccine series.  When compared with the 13 year olds, each increasing age group showed 
an increase in the odds of both initiating and completing the vaccine series.  Compared to 
non-Hispanic whites, Hispanic teens were 1.5 times more likely to initiate the vaccine 
series (p=<0.001), but they were less likely to complete the series (OR=0.70, p=<0.001).  
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Blacks were least likely to complete (OR=0.46).  White teens were most likely to 
complete the vaccine series compared to all race/ethnicity categories.   
 
Table 4. Bivariate Analysis Using Logistic Regression Assessing the Association of 
Demographic Characteristics and Vaccination Initiation of NIS-Teen 2011 HPV 
Vaccination Study Population 
 
Variable OR CI p-value 
SEX       
Male REF REF REF 
Female 9.86 9.29-10.46 <0.001 
  
      
AGE       
13 REF REF REF 
14 1.23 1.14-1.33 <0.001 
15 1.5 1.34-1.61 <0.001 
16 1.54 1.43-1.66 <0.001 
17 1.74 1.62-1.88 <0.001 
  
      
RACE/ETHNICITY       
Non-Hispanic White REF REF REF 
Non-Hispanic Black 0.96 0.90-1.04 0.32 
Hispanic 1.49 1.40-1.59 <0.001 
Non-Hispanic & 
Multi-race 1.06 0.97-1.15 0.19 
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Table 5. Bivariate Analysis Using Logistic Regression Assessing the Association of 
Demographic Characteristics and Vaccination Completion of NIS-Teen 2011 HPV 
Vaccination Study Population 
 
Variable OR CI p-value 
SEX       
Male REF REF REF 
Female 4.82 4.25-5.48 <0.001 
  
      
AGE       
13 REF REF REF 
14 1.22 1.07-1.40 0.004 
15 1.54 1.35-1.76 <0.001 
16 1.6 1.40-1.82 <0.001 
17 1.91 1.67-2.18 <0.001 
  
      
RACE/ETHNICITY       
Non-Hispanic White REF REF REF 
Non-Hispanic Black 0.46 0.40-0.52 <0.001 
Hispanic 0.67 0.60-0.75 <0.001 
Non-Hispanic & 
Multi-race 0.73 0.63-0.84 <0.001 
 
 
 
Additional analysis of the demographic characteristics influencing HPV 
vaccination initiation and completion was performed by including all independent 
variables in a multivariate logistic regression model.  Results are presented in Tables 8 
and 9.  Sex and age remained statistically significant predictors of both vaccine initiation 
and completion.  Females were 10.3 times more likely to initiate and 4.8 times more 
likely to complete the vaccine series.  As age increases, so too does the odds of an 
adolescent initiating or completing the series compared to 13 year olds.  However, in the 
multivariate model, the odds of a 14-yearold completing the series was no longer 
statistically significant.  Regarding race/ethnicity, the odds of a black adolescent 
initiating the series (0.90, p=0.021) now becomes statistically significant.  Non-Hispanic 
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other race and multi-race still were not significantly more or less likely than whites to 
initiate HPV vaccine. With the multivariate analysis, Hispanics are even more likely to 
initiate the series (OR=1.6, p=<0.001) but still less likely to complete the series 
(OR=0.80, p=<0.001) compared to whites. 
 
4.3 Socioeconomic characteristics 
Bivariate analysis using logistic regression assessed the association of 
socioeconomic characteristics with the initiation and completion of the HPV vaccine 
series.  The results are shown in Tables 6 and 7.  With regard to poverty status, teens 
falling below the poverty line were more likely to initiate the vaccine series (OR=1.2, 
p=<0.001) compared to teens above the poverty threshold and greater than $75,000.  
However, they were less likely to complete the vaccine series (OR=0.65, p=<0.001).  
Health insurance had a significant role in the completion of the vaccine series, as teens 
with at least one form of health insurance were 1.2 times more likely to complete than 
those with no insurance (p=<0.001). 
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Table 6. Bivariate Analysis Using Logistic Regression Assessing the Association of 
Socioeconomic Characteristics and Vaccination Initiation of NIS-Teen 2011 HPV 
Vaccination Study Population 
 
Variable OR CI p-value 
POVERTY STATUS       
Above Poverty ( > 
$75K) REF REF REF 
Above Poverty ( => 
$75K) 0.87 0.83-0.92 <0.001 
Below Poverty 1.2 1.12-1.28 <0.001 
  
      
INSURANCE       
Has no insurance REF REF REF 
Has at least one form 
of insurance 1.07 1.02-1.12 0.009 
 
 
 
Table 7. Bivariate Analysis Using Logistic Regression Assessing the Association of 
Socioeconomic Characteristics and Vaccination Completion of NIS-Teen 2011 HPV 
Vaccination Study Population 
 
Variable OR CI p-value 
POVERTY STATUS       
Above Poverty ( > 
$75K) REF REF REF 
Above Poverty ( => 
$75K) 0.83 0.76-0.91 <0.001 
Below Poverty 0.65 0.58-0.73 <0.001 
  
      
INSURANCE       
Has no insurance REF REF REF 
Has at least one form 
of insurance 1.24 1.14-1.34 <0.001 
 
 
Additional analysis of the socioeconomic characteristics influencing HPV 
vaccination initiation and completion was performed by including all independent 
variables in a multivariate logistic regression model.  Results are presented in Tables 8 
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and 9.  Regarding initiation of the series, both poverty status and health insurance status 
remained statistically significant where adolescents below poverty and having at least one 
form of health insurance were most likely to initiate.  However, poverty status is no 
longer significant when it comes to completion of the series. 
 
Table 8. Multivariate Analysis Using Logistic Regression Assessing the Association 
of Demographic and Socioeconomic Characteristics and Vaccination Initiation of 
NIS-Teen 2011 HPV Vaccination Study Population 
 
Variable OR CI p-value 
SEX       
Male REF REF REF 
Female 10.29 9.67-10.94 <0.001 
AGE       
13 REF REF REF 
14 1.28 1.18-1.40 <0.001 
15 1.62 1.49-1.76 <0.001 
16 1.74 1.60-1.89 <0.001 
17 2 1.84-2.18 <0.001 
RACE/ETHNICITY       
Non-Hispanic White REF REF REF 
Non-Hispanic Black 0.9 0.83-0.98 0.021 
Hispanic 1.56 1.45-1.69 <0.001 
Non-Hispanic & 
Multi-race 1.02 0.93-1.13 0.656 
POVERTY STATUS       
Above Poverty ( > 
$75K) REF REF REF 
Above Poverty ( => 
$75K) 0.85 0.80-0.90 <0.001 
Below Poverty 1.2 1.10-1.31 <0.001 
INSURANCE       
Has no insurance REF REF REF 
Has at least one form 
of insurance 1.18 1.11-1.24 <0.001 
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Table 9. Multivariate Analysis Using Logistic Regression Assessing the Association 
of Demographic and Socioeconomic Characteristics and Vaccination Completion of 
NIS-Teen 2011 HPV Vaccination Study Population 
 
Variable OR CI p-value 
SEX       
Male REF REF REF 
Female 4.61 4.05-5.26 <0.001 
AGE       
13 REF REF REF 
14 1.19 1.02-1.37 0.023 
15 1.45 1.25-1.67 <0.001 
16 1.51 1.31-1.73 <0.001 
17 1.76 1.53-2.03 <0.001 
RACE/ETHNICITY       
Non-Hispanic White REF REF REF 
Non-Hispanic Black 0.52 0.45-0.60 <0.001 
Hispanic 0.8 0.71-0.91 <0.001 
Non-Hispanic & 
Multi-race 0.75 0.64-0.88 <0.001 
POVERTY STATUS       
Above Poverty ( > 
$75K) REF REF REF 
Above Poverty ( => 
$75K) 0.95 0.86-1.04 0.268 
Below Poverty 0.92 0.81-1.06 0.24 
INSURANCE       
Has no insurance REF REF REF 
Has at least one form 
of insurance 1.15 1.05-1.26 0.003 
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Table 10. Poverty Status and Race/Ethnicity of NIS-Teen 2011 HPV Vaccination 
Study Population 
 
Poverty Status 
Teens Above 
Poverty ( > 
$75K)  
N (%) 
Teens Above 
Poverty ( => 
$75K) 
N (%) 
Teens 
Below 
Poverty 
N (%) Total 
Non-Hispanic White 12657 (52) 9796 (40) 1838 (8) 24291 
Non-Hispanic Black 1027 (22) 2138 (46) 1440 (31) 4605 
Hispanic 1226 (23) 2236 (42) 1888 (35) 5350 
Non-Hispanic & Multi-
race 1324 (42) 1268 (40) 581 (18) 3173 
Total       37419* 
*Total represents 94% of the NIS-Teen Vaccine study population 
 
 
 
Table 11. Medicaid Insurance Status and Race/Ethnicity of NIS-Teen 2011 HPV 
Vaccination Study Population 
 
  
Teens with Any Medicaid 
Health Insurance  
N (%) Total 
Non-Hispanic White 1634 (14) 11700 
Non-Hispanic Black 731 (44) 1663 
Hispanic 930 (34) 2732 
Non-Hispanic & Multi-
race 323 (25) 1271 
Total 3618 17471* 
*Total represents 44% of the NIS-Teen Vaccine study population 
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Table 12. Vaccines for Children Status and Race/Ethnicity of NIS-Teen 2011 HPV 
Vaccination Study Population 
 
  
Teens who are VFC Eligible  
N (%) Total 
Non-Hispanic White 3129 (20) 15922 
Non-Hispanic Black 1323 (56) 2400 
Hispanic 1737 (56) 3226 
Non-Hispanic & Multi-
race 1017 (52) 1947 
Total 23564* 
*Total represents 59% of the NIS-Teen Vaccine study population 
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CHAPTER V 
DISCUSSION AND CONCLUSION 
5.1 Discussion 
More than 40 genital human papillomaviruses (HPV) account for the most 
common STI in the United States, which disproportionality affects adolescents [2].  
Several types of HPVs have been shown to cause different forms of cancer, mainly 
cervical.  Two vaccines, Gardasil® and Cervarix®, were developed to promote immunity 
from the most common types of HPVs in order to prevent HPV-type-related cervical 
cancer, cervical cancer precursors, and anogenital warts.  The Advisory Committee on 
Immunization Practices (ACIP) asks physicians to recommend either vaccine to 
adolescents between the ages of 11 and 12 in order to complete vaccination before sexual 
debut [4].  The Healthy People 2020 target is to have 80% of female adolescents 
complete the three dose series by the ages 13-15 [26].  The Centers for Disease Control 
and Prevention (CDC) recognizes the yearly increase in vaccine coverage since 2006; 
however, the numbers continue to fall short of the Healthy People 2020 goals [30]. 
The purpose of this work was to examine the association between specific 
demographic and socioeconomic characteristics with both initiation and completion of 
the human papillomavirus vaccine series.  Studies on the characteristics that describe the 
adolescent population that completed the series will allow public health and health care 
professionals implement appropriate interventions aimed at improving adolescent 
vaccination rates. 
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Demographic Characteristics 
Sex 
In this study, sex was clearly associated with both initiation and completion of the 
vaccine series where females were 10.3 times more likely than males to initiate and 4.6 
times more likely to complete.  However, it was important to note that it was not until 
late 2011 that ACIP began recommending adolescent males receive the vaccine.  
Statistics regarding gender should be reassessed after at least one full year of 
implementation of male recommendations.  It should be noted that there was a 55% 
change in the odds ratio between initiation and completion for males.  This shows that 
males were doing a great job of completing the series if they initiated the process.  No 
current studies look at the association between sex and initiation or completion rates. 
 
Age 
There was also a significant association between age and receipt of the HPV 
vaccine.  As age increased from 13 to 17, the likelihood of both initiation and completion 
increased.  Healthy People 2020 aimed to have girls complete the series by ages 13 to 15, 
so the findings here are troubling. Based on provider surveys, this age difference may be 
associated with parents delaying vaccine initiation or provider preference to recommend 
to older patients due to the sexual association to this vaccine [28].  Previous studies also 
showed providers prefer to strongly recommend the HPV vaccine to older adolescents 
(6).  Vadaparampil, et al., found 34.6% of providers “always” recommend the vaccine to 
early adolescents, 50% to middle adolescents, and 52.7% to late adolescents [22].  Kester, 
et al., found that only 56% of 11 to 12 year old girls received a recommendation for the 
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HPV vaccine from their healthcare provider [31].  A recent study showed younger girls 
(ages 9-13 years old) had higher levels of HPV antibodies than older girls (aged 16-26 
years old) after receiving the vaccine [36].  This should encourage providers to strongly 
recommend this vaccine to their younger patients. 
 
Race/Ethnicity 
Based on the analysis, Hispanics were more likely than whites to initiate the 
series.  This was good news, since they were at highest risk of invasive cervical cancer 
[18].  However, the news was short-lived, since they were less likely than whites to 
complete the series.   While it was less likely for black adolescents to initiate the series, 
their odds of initiation were not statistically different from that of their white 
counterparts.  It was the completion rate that was of concern.  They were half as likely to 
complete the vaccine series, which was necessary to confer the necessary resistance to the 
virus.  This information was troubling since blacks are twice as likely as whites to be 
diagnosed with cervical cancer [18].   The initiation results were different than previous 
studies using 2008 and 2009 NIS-Teen data, which showed race/ethnicity was not 
associated with initiation rates [26, 31].  However, the completion results in this analysis 
were consistent with those previous studies, which showed blacks and Hispanics were 
less likely than whites to complete the series [26, 31].   
Studies showed that providers vary their recommendation of the HPV vaccine.  
One study, using 2009 NIS-Teen data, showed providers were less likely to recommend 
the vaccine to blacks compared to whites [37].  Another showed Hispanic providers were 
more likely to always recommend the vaccine to early adolescent Hispanic patients 
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compared to non-Hispanic providers [22].  Some clinicians did not encourage the vaccine 
if they perceived the patient to be at low risk of HPV infection [28].  These could be 
reasons behind the variance in initiation and completion rates based on race/ethnicity. 
 
Socioeconomic Characteristics 
Poverty Status 
While poverty status was not associated with the completion of the series, it was 
associated with initiation.  Adolescents below the 2009 poverty level were more likely to 
initiate the series compared to those above poverty.  This was consistent with other 
studies, showing income and insurance were significantly associated with initiation.  
Patients in the lowest income group and Medicaid eligible had a higher initiation rate 
[26]. 
A crosstab was run to determine if poverty status may be linked to race/ethnicity 
rates of initiation and completion for this study.  However, Table 10 showed there was 
very little difference between Hispanic and black adolescents in each of the three poverty 
categories.  Therefore, it was not believed that race/ethnicity played a role in poverty 
status’ association with initiation and completion. 
 
Health Insurance Status 
Health insurance status was often related to poverty status, as lower incomes can 
provide eligibility to Medicaid, SCHIP, and/or Vaccines for Children (VFC). 
It was of no surprise that this analysis showed having health insurance was associated 
with both initiation and completion of the vaccine series.   This was consistent with 
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previous studies [26].  This study, however, did not break out the different forms of 
insurance available to the patients.  Other studies look at private/employer insurance 
compared to that of Medicaid and VFC.  VFC eligible, insured girls were more likely to 
initiate yet less likely to complete the series compared to girls with private insurance 
[37].  Another study showed individuals with Medicaid or SCHIP were more likely to 
receive the vaccine [37].  However, those with public insurance are 24% less likely to 
complete the series when compared to those with private insurance, specifically those 
who are VFC eligible [29]. 
While VFC may be influential in promoting initiation, it falls short of facilitating 
completion, which puts economically vulnerable populations at greater risk of HPV-
related morbidities [29]. One hypothesis behind VFC’s success in vaccine initiation is 
that patients, when they come in contact with the healthcare system for well or sick visits, 
are offered the vaccine.  Since it bears little or no cost, the patient is likely to accept the 
vaccine [29].  Another study shows that VFC providers are more likely than non-VFC 
providers to always recommend the vaccine [22]. 
A crosstab was run to determine if health insurance status may be linked to 
race/ethnicity rates of initiation and completion for this study.  However, Tables 11 and 
12 showed there was very little difference between Hispanic and black adolescents who 
were Medicaid beneficiaries or VFC eligible who initiated the vaccine series. 
 
5.2 Study Limitations 
The results of this study are subject to some limitations.  This study only extracted 
data on vaccination status from a parent’s or guardian’s recall and on-hand shot card 
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based on telephone surveys, and responses from participants may reflect recall bias.  
Analysis using only the population with verification from the provider was not 
incorporated. 
Even though NIS has begun using cellular telephones in their random-digit 
dialing survey, the number of households using only cellular telephones may not be 
accurately represented in the survey population.  Of those adolescents who were a part of 
NIS-Teen 2011, 1 703 were excluded from the study population due to lack of 
information regarding HPV vaccine status. Due to lack of information regarding 
household income, 2 255 additional teens were excluded from any analysis regarding 
poverty status. 
Although health insurance status was found to be a significant predictor, a large 
percentage of data on health insurance status was not available either due to unknown or 
non-response.  Questions from the health insurance status section were addressed toward 
the end of the interview, and some respondents who did not complete the demographic 
section earlier in the survey did not reach the health insurance questions.  The NIS 
researchers also addressed the possibility that respondents may have broken off the 
interview prior to concluding the survey.  It is also unknown whether the health insurance 
covered all or only a portion of the cost. 
 
5.3 Recommendations 
5.3.1 Increase Efficacy of Provider Influence 
Studies have shown that provider recommendation is the most influential force 
behind parental acceptance of the HPV vaccine [26].  As discussed before, providers 
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often have difficulty either presenting or convincing parents to begin the vaccine regimen 
between the ages of 11 and 12 [28].  There are three things providers can do in order to 
help begin the discussion and ensure compliance with the vaccine dosage. 
Parents should be sent an informational handout covering HPV, its associated 
cancers, and proven efficacy of available vaccines.  This can be sent via mail or email 
before the clinic visit or provided to the parent upon arrival at the provider’s office.  This 
will give parents more knowledge about the importance of this vaccine and time to digest 
presented information.  The provider can, then, spend time answering important 
questions, as opposed to explaining the vaccine from the beginning. 
Part of this handout and the provider discussion must emphasize the importance 
of the three doses needed for complete immunization.  One dose does not confer 
complete resistance to vaccine-type HPV.  When parents are more aware of the need for 
all three doses, they are more likely to prioritize getting back to the provider for future 
doses.  For many parents, remembering the dosing schedule is lost in a laundry list of 
their adolescent’s needs.  A reminder or recall system needs to be in place to allow 
parents adequate notice to schedule the next vaccine. 
If parents ask to delay the vaccine for a few years, providers should point out the 
number of adolescent well checkups decreases significantly after the 11 and 12 year old 
well checkups [27].  School vaccines are no longer needed, so parents rarely take their 
teen to a provider unless sick.  Because the number of visits is typically lower, the 
opportunities for vaccination decrease.  If parents choose to delay, it will increase the 
burden to get their child to a provider to receive future vaccines.  The goal is to have 80% 
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of adolescent females immunized by the ages 13 to 15, which is typically before sexual 
debut. 
 
5.3.2 Increase Adolescent Participation in Vaccination Decision 
Many teens are unaware of HPV or its available vaccines [31].  Hearing about it 
for the first time from a provider can be confusing, and teens will defer to their parents’ 
decision.  Teens need to be able to advocate for themselves, but they need to be educated 
in order to do so.  Looping back to the recommendation where providers send an 
informational handout prior to the clinic visit, teens should take the time to learn from 
this handout alongside their parent.  Risks and consequences are difficult for the 
adolescent mind, thus the handout needs to present these in plain language for both adults 
and adolescents to grasp.  Statistics regarding higher risk of HPV infection for 
adolescents and asymptomatic nature of most HPV infections is important for the teens in 
order to understand they have a higher risk of contracting this virus than any other age 
group.  Perhaps if teens can gain a better understanding of the benefits surrounding the 
HPV vaccine, they will want to advocate for themselves, requesting permission to have 
the vaccine or, at least, a frank conversation about receiving it in the future. 
 
5.3.3 Reduce Other Barriers for Vaccination Completion 
When teens, parents, and providers do agree to begin the vaccination process, the 
final two doses can present a barrier to completion of the series.  Not only do parents 
have to remember to schedule the provider visit, they have to take time out of their 
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schedule to get the teen back for a follow-up appointment.  Transportation is not readily 
available for many teens and their parents, thus preventing further dose administration. 
School or neighborhood-based programs could reduce the barrier caused by 
transportation and time.  By having vaccine providers come to a school, after-school 
program or, neighborhood, the need to remember to schedule a visit and find time and 
transportation for the visit is removed.  More teens could be fully immunized. 
 
5.3.4 Longitudinal Study for Vaccine Initiation 
Many parents choose to delay the HPV vaccine for many reasons, not the least of 
which is belief that their child is not yet sexually active [28].  Further research needs to 
be conducted with parents to assess future vaccination behavior.  Questions to be 
addressed are whether the teen is vaccinated in future visits and at what age does the 
parent consent to vaccination.  Longitudinal studies can be set up in pediatric practices 
where parents who choose to delay or refuse the vaccine are enrolled.  If the teen is 
eventually vaccinated, parents can be surveyed to determine why they now believe the 
vaccine to be appropriate and the age of the teen at the time of vaccination.  If the teen is 
not vaccinated, parents can be surveyed to determine reasons.  Information gathered from 
this kind of study can help tailor provider and public health officials’ efforts in 
convincing parents to make the decision to vaccinate against HPV in a timely manner. 
 
5.4 Conclusion 
Each year both HPV vaccines have been on the market, vaccination rates have 
continued to increase.  Healthy People 2020 aims to have 80% of adolescent girls 
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covered with three doses of either vaccine between the ages of 13 and 15.  In order to 
achieve these goals, the vaccination initiation rates need to continue, but more 
importantly, the completion rates need to be 100% of those who initiate.  Completion 
rates are lower for blacks and Hispanics who are a higher risk of HPV-related morbidities 
than their white counterparts.  Public health officials need to work with providers to 
recommend the vaccine at an earlier age, impart the importance of receiving all three 
doses, and prove the effectiveness of both vaccines in reducing HPV incidence and thus, 
HPV-related morbidities.  Officials also need to find ways to reduce barriers to receipt of 
the second two doses of the vaccine and help facilitate increasing rates of completion in 
the United States. 
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